Lantheus Holdings (LNTH) Income towards Parent Company (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Income towards Parent Company of $118.4 million for Q1 2026, up 62.34% year-over-year from $72.9 million in Q1 2025, and down 16.68% quarter-over-quarter from $142.1 million in Q4 2025.
Lantheus Holdings (LNTH) Income towards Parent Company (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Income towards Parent Company for 13 consecutive years, with $118.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company rose 62.34% year-over-year to $118.4 million; the TTM figure through Mar 2026 stood at $367.1 million (up 566.01% YoY), while the FY2025 annual figure was $321.6 million, up 1657.63% from the prior year.
- Income towards Parent Company retreated to $118.4 million in Q1 2026 per LNTH's latest filing, from $142.1 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $142.1 million in Q4 2025 and bottomed at -$344.9 million in Q4 2024.
- Historically, Income towards Parent Company has averaged $45.4 million across 5 years, with a median of $72.9 million in 2025.
- On a YoY basis, Income towards Parent Company climbed as much as 4769.26% in 2024 and fell as far as 440.24% in 2024.
- Lantheus Holdings' Income towards Parent Company stood at -$119.2 million in 2022, then soared by 185.05% to $101.4 million in 2023, then tumbled by 440.24% to -$344.9 million in 2024, then jumped by 141.21% to $142.1 million in 2025, then slipped by 16.68% to $118.4 million in 2026.
- Business Quant data shows LNTH's Income towards Parent Company at $118.4 million in Q1 2026, $142.1 million in Q4 2025, and $27.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Lantheus Holdings | 6.52 Bn | 5.93 Bn | 241.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.03 Mn |
| Mar 31, 2026 | 118.42 Mn |
| Dec 31, 2025 | 142.12 Mn |
| Sep 30, 2025 | 27.77 Mn |
| Jun 30, 2025 | 78.76 Mn |
| Mar 31, 2025 | 72.95 Mn |
| Dec 31, 2024 | -344.88 Mn |
| Sep 30, 2024 | 131.09 Mn |
| Jun 30, 2024 | 62.07 Mn |
| Mar 31, 2024 | 131.07 Mn |
| Dec 31, 2023 | 101.36 Mn |
| Sep 30, 2023 | 131.96 Mn |
| Jun 30, 2023 | 94.13 Mn |
| Mar 31, 2023 | -2.81 Mn |
| Dec 31, 2022 | -119.19 Mn |
| Sep 30, 2022 | 61.23 Mn |
| Jun 30, 2022 | 43.06 Mn |
| Mar 31, 2022 | 42.96 Mn |
| Dec 31, 2021 | -40.22 Mn |
| Sep 30, 2021 | -13.42 Mn |